As a rate-limiting enzyme in the endogenous serine de novo synthesis pathway, 3-Phosphoglycerate dehydrogenase (PHGDH) has been widely concerned about its role in a variety of tumors including colon cancer and the development of inhibitors. Here, PHGDH is linked to malignant colon neoplasm.